Literature DB >> 2818711

Early treatment of Campylobacter jejuni enteritis.

M D Williams1, J B Schorling, L J Barrett, S M Dudley, I Orgel, W C Koch, D S Shields, S M Thorson, J A Lohr, R L Guerrant.   

Abstract

The bacteriologic and clinical effects of early antibiotic treatment of Campylobacter jejuni enteritis were studied. Erythromycin rapidly eliminated C. jejuni from stools, whereas trimethoprim-sulfamethoxazole did not. Despite its bacteriologic effectiveness, erythromycin did not reduce the duration or severity of diarrhea, abdominal pain, or other symptoms.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2818711      PMCID： PMC171468          DOI： 10.1128/AAC.33.2.248

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Campylobacter enteritis.

Authors:  B J Murray
Journal:  Ann Intern Med       Date:  1983-06       Impact factor: 25.391

2.  Effect of erythromycin on the fecal excretion of Campylobacter fetus subspecies jejuni.

Authors:  T Pitkanen; T Pettersson; A Pomka; T U Kosunen
Journal:  J Infect Dis       Date:  1982-01       Impact factor: 5.226

3.  Susceptibility of Campylobacter fetus subsp. jejuni to twenty-nine antimicrobial agents.

Authors:  R Vanhoof; M P Vanderlinden; R Dierickx; S Lauwers; E Yourassowsky; J P Butzler
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

Review 4.  Campylobacter enteritis.

Authors:  M J Blaser; L B Reller
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

5.  Sulfamethoxazole- trimethoprim versus ampicillin in treatment of acute invasive diarrhea in adults.

Authors:  F A Barada; R L Guerrant
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

6.  Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis.

Authors:  B J Anders; B A Lauer; J W Paisley; L B Reller
Journal:  Lancet       Date:  1982-01-16       Impact factor: 79.321

7.  Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea.

Authors:  H E Pichler; G Diridl; K Stickler; D Wolf
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

8.  Campylobacter enteritis in Denver.

Authors:  M J Blaser; L B Reller; N W Luechtefeld; W L Wang
Journal:  West J Med       Date:  1982-04

9.  Erythromycin in treatment of Campylobacter enteritis in children.

Authors:  C H Pai; F Gillis; E Tuomanen; M I Marks
Journal:  Am J Dis Child       Date:  1983-03

10.  Campylobacter enteritis: clinical and epidemiologic features.

Authors:  M J Blaser; I D Berkowitz; F M LaForce; J Cravens; L B Reller; W L Wang
Journal:  Ann Intern Med       Date:  1979-08       Impact factor: 25.391
View more
  10 in total

1.  Antimicrobial resistance of Campylobacter isolates from retail meat in the United States between 2002 and 2007.

Authors:  S Zhao; S R Young; E Tong; J W Abbott; N Womack; S L Friedman; P F McDermott
Journal:  Appl Environ Microbiol       Date:  2010-10-22       Impact factor: 4.792

Review 2.  Management of infectious diarrhoea.

Authors:  A C Casburn-Jones; M J G Farthing
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

Review 3.  Minding the gap: The impact of B-cell tolerance on the microbial antibody repertoire.

Authors:  Joel Finney; Akiko Watanabe; Garnett Kelsoe; Masayuki Kuraoka
Journal:  Immunol Rev       Date:  2019-09-27       Impact factor: 12.988

4.  High-level resistance to trimethoprim in clinical isolates of Campylobacter jejuni by acquisition of foreign genes (dfr1 and dfr9) expressing drug-insensitive dihydrofolate reductases.

Authors:  A Gibreel; O Sköld
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 5.  Host-pathogen interactions in Campylobacter infections: the host perspective.

Authors:  Riny Janssen; Karen A Krogfelt; Shaun A Cawthraw; Wilfrid van Pelt; Jaap A Wagenaar; Robert J Owen
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

6.  Susceptibilities of fluoroquinolone-resistant strains of Campylobacter jejuni to 11 oral antimicrobial agents.

Authors:  J L Gomez-Garces; R Cogollos; J L Alos
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

7.  Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli isolated in Sweden: a 10-year follow-up report.

Authors:  E Sjögren; B Kaijser; M Werner
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 8.  Role of antimicrobials in the treatment of adult patients presenting to the emergency department with acute gastroenteritis - A mini review.

Authors:  Omar Abbas Ahmed Malik
Journal:  Pak J Med Sci       Date:  2017 Mar-Apr       Impact factor: 1.088

9.  A novel mouse model of Campylobacter jejuni enteropathy and diarrhea.

Authors:  Natasa Giallourou; Gregory L Medlock; David T Bolick; Pedro Hqs Medeiros; Solanka E Ledwaba; Glynis L Kolling; Kenneth Tung; Patricia Guerry; Jonathan R Swann; Richard L Guerrant
Journal:  PLoS Pathog       Date:  2018-05-23       Impact factor: 6.823

10.  Pediatric campylobacteriosis in northern Taiwan from 2003 to 2005.

Authors:  Ji-Rong Yang; Ho-Sheng Wu; Chuen-Sheue Chiang; Jung-Jung Mu
Journal:  BMC Infect Dis       Date:  2008-10-31       Impact factor: 3.090
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.